WO2021092684A1 - Chewing gum containing synergistic medicinal compounds - Google Patents
Chewing gum containing synergistic medicinal compounds Download PDFInfo
- Publication number
- WO2021092684A1 WO2021092684A1 PCT/CA2020/051530 CA2020051530W WO2021092684A1 WO 2021092684 A1 WO2021092684 A1 WO 2021092684A1 CA 2020051530 W CA2020051530 W CA 2020051530W WO 2021092684 A1 WO2021092684 A1 WO 2021092684A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- delta
- polyisobutylene
- gum
- chewing gum
- Prior art date
Links
- 235000015218 chewing gum Nutrition 0.000 title claims abstract description 62
- 229940112822 chewing gum Drugs 0.000 title claims abstract description 61
- 230000002195 synergetic effect Effects 0.000 title claims abstract description 43
- 150000001875 compounds Chemical class 0.000 title claims abstract description 19
- 229930003827 cannabinoid Natural products 0.000 claims abstract description 75
- 239000003557 cannabinoid Substances 0.000 claims abstract description 75
- 229940065144 cannabinoids Drugs 0.000 claims abstract description 46
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 37
- 239000004615 ingredient Substances 0.000 claims description 29
- ZLYNXDIDWUWASO-UHFFFAOYSA-N 6,6,9-trimethyl-3-pentyl-8,10-dihydro-7h-benzo[c]chromene-1,9,10-triol Chemical compound CC1(C)OC2=CC(CCCCC)=CC(O)=C2C2=C1CCC(C)(O)C2O ZLYNXDIDWUWASO-UHFFFAOYSA-N 0.000 claims description 24
- 229950011318 cannabidiol Drugs 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 23
- 229920000578 graft copolymer Polymers 0.000 claims description 22
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims description 21
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 21
- 229920002367 Polyisobutene Polymers 0.000 claims description 18
- 235000002982 Boswellia sp Nutrition 0.000 claims description 17
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims description 17
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims description 17
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims description 17
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims description 17
- AAXZFUQLLRMVOG-UHFFFAOYSA-N 2-methyl-2-(4-methylpent-3-enyl)-7-propylchromen-5-ol Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCC)=CC(O)=C21 AAXZFUQLLRMVOG-UHFFFAOYSA-N 0.000 claims description 16
- NAGBBYZBIQVPIQ-UHFFFAOYSA-N 6-methyl-3-pentyl-9-prop-1-en-2-yldibenzofuran-1-ol Chemical compound C1=CC(C(C)=C)=C2C3=C(O)C=C(CCCCC)C=C3OC2=C1C NAGBBYZBIQVPIQ-UHFFFAOYSA-N 0.000 claims description 16
- 229960004242 dronabinol Drugs 0.000 claims description 16
- 239000000284 extract Substances 0.000 claims description 14
- YJYIDZLGVYOPGU-XNTDXEJSSA-N 2-[(2e)-3,7-dimethylocta-2,6-dienyl]-5-propylbenzene-1,3-diol Chemical compound CCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 YJYIDZLGVYOPGU-XNTDXEJSSA-N 0.000 claims description 12
- YJYIDZLGVYOPGU-UHFFFAOYSA-N cannabigeroldivarin Natural products CCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 YJYIDZLGVYOPGU-UHFFFAOYSA-N 0.000 claims description 12
- HCAWPGARWVBULJ-IAGOWNOFSA-N delta8-THC Chemical compound C1C(C)=CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 HCAWPGARWVBULJ-IAGOWNOFSA-N 0.000 claims description 12
- QHCQSGYWGBDSIY-HZPDHXFCSA-N tetrahydrocannabinol-c4 Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCC)=CC(O)=C3[C@@H]21 QHCQSGYWGBDSIY-HZPDHXFCSA-N 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- UCONUSSAWGCZMV-HZPDHXFCSA-N Delta(9)-tetrahydrocannabinolic acid Chemical compound C([C@H]1C(C)(C)O2)CC(C)=C[C@H]1C1=C2C=C(CCCCC)C(C(O)=O)=C1O UCONUSSAWGCZMV-HZPDHXFCSA-N 0.000 claims description 10
- 208000002193 Pain Diseases 0.000 claims description 10
- -1 canabivarol (CBV) Chemical compound 0.000 claims description 10
- 229920001206 natural gum Polymers 0.000 claims description 10
- 239000011347 resin Substances 0.000 claims description 10
- 229920005989 resin Polymers 0.000 claims description 10
- ZROLHBHDLIHEMS-HUUCEWRRSA-N (6ar,10ar)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCC)=CC(O)=C3[C@@H]21 ZROLHBHDLIHEMS-HUUCEWRRSA-N 0.000 claims description 9
- ZROLHBHDLIHEMS-UHFFFAOYSA-N Delta9 tetrahydrocannabivarin Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCC)=CC(O)=C3C21 ZROLHBHDLIHEMS-UHFFFAOYSA-N 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- OQCOBNKTUMOOHJ-RSGMMRJUSA-N (5as,6s,9r,9ar)-1,6-dihydroxy-6-methyl-3-pentyl-9-prop-1-en-2-yl-7,8,9,9a-tetrahydro-5ah-dibenzofuran-2-carboxylic acid Chemical compound C1=2C(O)=C(C(O)=O)C(CCCCC)=CC=2O[C@H]2[C@@H]1[C@H](C(C)=C)CC[C@]2(C)O OQCOBNKTUMOOHJ-RSGMMRJUSA-N 0.000 claims description 8
- HJMCQDCJBFTRPX-RSGMMRJUSA-N (5as,6s,9r,9ar)-1,6-dihydroxy-6-methyl-3-pentyl-9-prop-1-en-2-yl-7,8,9,9a-tetrahydro-5ah-dibenzofuran-4-carboxylic acid Chemical compound [C@H]1([C@@H](CC[C@@]2(O)C)C(C)=C)[C@@H]2Oc2c(C(O)=O)c(CCCCC)cc(O)c21 HJMCQDCJBFTRPX-RSGMMRJUSA-N 0.000 claims description 8
- RBEAVAMWZAJWOI-MTOHEIAKSA-N (5as,6s,9r,9ar)-6-methyl-3-pentyl-9-prop-1-en-2-yl-7,8,9,9a-tetrahydro-5ah-dibenzofuran-1,6-diol Chemical compound C1=2C(O)=CC(CCCCC)=CC=2O[C@H]2[C@@H]1[C@H](C(C)=C)CC[C@]2(C)O RBEAVAMWZAJWOI-MTOHEIAKSA-N 0.000 claims description 8
- TZGCTXUTNDNTTE-DYZHCLJRSA-N (6ar,9s,10s,10ar)-6,6,9-trimethyl-3-pentyl-7,8,10,10a-tetrahydro-6ah-benzo[c]chromene-1,9,10-triol Chemical compound O[C@@H]1[C@@](C)(O)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 TZGCTXUTNDNTTE-DYZHCLJRSA-N 0.000 claims description 8
- YEDIZIGYIMTZKP-UHFFFAOYSA-N 1-methoxy-6,6,9-trimethyl-3-pentylbenzo[c]chromene Chemical compound C1=C(C)C=C2C3=C(OC)C=C(CCCCC)C=C3OC(C)(C)C2=C1 YEDIZIGYIMTZKP-UHFFFAOYSA-N 0.000 claims description 8
- TWKHUZXSTKISQC-UHFFFAOYSA-N 2-(5-methyl-2-prop-1-en-2-ylphenyl)-5-pentylbenzene-1,3-diol Chemical compound OC1=CC(CCCCC)=CC(O)=C1C1=CC(C)=CC=C1C(C)=C TWKHUZXSTKISQC-UHFFFAOYSA-N 0.000 claims description 8
- COURSARJQZMTEZ-UHFFFAOYSA-N 2-(5-methyl-2-prop-1-en-2-ylphenyl)-5-propylbenzene-1,3-diol Chemical compound OC1=CC(CCC)=CC(O)=C1C1=CC(C)=CC=C1C(C)=C COURSARJQZMTEZ-UHFFFAOYSA-N 0.000 claims description 8
- XWIWWMIPMYDFOV-UHFFFAOYSA-N 3,6,6,9-tetramethylbenzo[c]chromen-1-ol Chemical compound C1=C(C)C=C2OC(C)(C)C3=CC=C(C)C=C3C2=C1O XWIWWMIPMYDFOV-UHFFFAOYSA-N 0.000 claims description 8
- GGVVJZIANMUEJO-UHFFFAOYSA-N 3-butyl-6,6,9-trimethylbenzo[c]chromen-1-ol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCC)C=C3OC(C)(C)C2=C1 GGVVJZIANMUEJO-UHFFFAOYSA-N 0.000 claims description 8
- QUYCDNSZSMEFBQ-UHFFFAOYSA-N 3-ethyl-6,6,9-trimethylbenzo[c]chromen-1-ol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CC)C=C3OC(C)(C)C2=C1 QUYCDNSZSMEFBQ-UHFFFAOYSA-N 0.000 claims description 8
- IPGGELGANIXRSX-RBUKOAKNSA-N 3-methoxy-2-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylphenol Chemical compound COC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 IPGGELGANIXRSX-RBUKOAKNSA-N 0.000 claims description 8
- GKVOVXWEBSQJPA-UONOGXRCSA-N 5-methyl-2-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]benzene-1,3-diol Chemical compound CC(=C)[C@@H]1CCC(C)=C[C@H]1C1=C(O)C=C(C)C=C1O GKVOVXWEBSQJPA-UONOGXRCSA-N 0.000 claims description 8
- VNGQMWZHHNCMLQ-UHFFFAOYSA-N 6-methyl-3-pentyl-9-propan-2-yldibenzofuran-1-ol Chemical compound C1=CC(C(C)C)=C2C3=C(O)C=C(CCCCC)C=C3OC2=C1C VNGQMWZHHNCMLQ-UHFFFAOYSA-N 0.000 claims description 8
- IPGGELGANIXRSX-UHFFFAOYSA-N Cannabidiol monomethyl ether Natural products COC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 IPGGELGANIXRSX-UHFFFAOYSA-N 0.000 claims description 8
- REOZWEGFPHTFEI-JKSUJKDBSA-N Cannabidivarin Chemical compound OC1=CC(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-JKSUJKDBSA-N 0.000 claims description 8
- AEMUKTQSTGYTRH-UHFFFAOYSA-N Cannabigerol monoethyl ether Natural products CCCCCc1cc(O)c(CC=C(/C)CCC=C(C)C)c(OCC)c1 AEMUKTQSTGYTRH-UHFFFAOYSA-N 0.000 claims description 8
- HRHJHXJQMNWQTF-UHFFFAOYSA-N cannabichromenic acid Chemical compound O1C(C)(CCC=C(C)C)C=CC2=C1C=C(CCCCC)C(C(O)=O)=C2O HRHJHXJQMNWQTF-UHFFFAOYSA-N 0.000 claims description 8
- IGHTZQUIFGUJTG-UHFFFAOYSA-N cannabicyclol Chemical compound O1C2=CC(CCCCC)=CC(O)=C2C2C(C)(C)C3C2C1(C)CC3 IGHTZQUIFGUJTG-UHFFFAOYSA-N 0.000 claims description 8
- QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 claims description 8
- 229920002674 hyaluronan Polymers 0.000 claims description 8
- 229960003160 hyaluronic acid Drugs 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- YKKHSYLGQXKVMO-HZPDHXFCSA-N (6ar,10ar)-1-hydroxy-6,6,9-trimethyl-3-pentyl-6a,7,10,10a-tetrahydrobenzo[c]chromene-2-carboxylic acid Chemical compound C([C@H]1C(C)(C)O2)C=C(C)C[C@H]1C1=C2C=C(CCCCC)C(C(O)=O)=C1O YKKHSYLGQXKVMO-HZPDHXFCSA-N 0.000 claims description 7
- IQSYWEWTWDEVNO-ZIAGYGMSSA-N (6ar,10ar)-1-hydroxy-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromene-2-carboxylic acid Chemical compound C([C@H]1C(C)(C)O2)CC(C)=C[C@H]1C1=C2C=C(CCC)C(C(O)=O)=C1O IQSYWEWTWDEVNO-ZIAGYGMSSA-N 0.000 claims description 7
- WBRXESQKGXYDOL-DLBZAZTESA-N 5-butyl-2-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]benzene-1,3-diol Chemical compound OC1=CC(CCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WBRXESQKGXYDOL-DLBZAZTESA-N 0.000 claims description 7
- XXGMIHXASFDFSM-UHFFFAOYSA-N Delta9-tetrahydrocannabinol Natural products CCCCCc1cc2OC(C)(C)C3CCC(=CC3c2c(O)c1O)C XXGMIHXASFDFSM-UHFFFAOYSA-N 0.000 claims description 7
- 206010061218 Inflammation Diseases 0.000 claims description 7
- 230000004054 inflammatory process Effects 0.000 claims description 7
- 230000036407 pain Effects 0.000 claims description 7
- 230000008961 swelling Effects 0.000 claims description 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 6
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 6
- UCONUSSAWGCZMV-UHFFFAOYSA-N Tetrahydro-cannabinol-carbonsaeure Natural products O1C(C)(C)C2CCC(C)=CC2C2=C1C=C(CCCCC)C(C(O)=O)=C2O UCONUSSAWGCZMV-UHFFFAOYSA-N 0.000 claims description 6
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims description 6
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 claims description 6
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 claims description 6
- 235000007746 carvacrol Nutrition 0.000 claims description 6
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 6
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 claims description 6
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 claims description 6
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 claims description 6
- 229940068065 phytosterols Drugs 0.000 claims description 5
- IXJXRDCCQRZSDV-GCKMJXCFSA-N (6ar,9r,10as)-6,6,9-trimethyl-3-pentyl-6a,7,8,9,10,10a-hexahydro-6h-1,9-epoxybenzo[c]chromene Chemical compound C1C[C@@H](C(O2)(C)C)[C@@H]3C[C@]1(C)OC1=C3C2=CC(CCCCC)=C1 IXJXRDCCQRZSDV-GCKMJXCFSA-N 0.000 claims description 4
- KXKOBIRSQLNUPS-UHFFFAOYSA-N 1-hydroxy-6,6,9-trimethyl-3-pentylbenzo[c]chromene-2-carboxylic acid Chemical compound O1C(C)(C)C2=CC=C(C)C=C2C2=C1C=C(CCCCC)C(C(O)=O)=C2O KXKOBIRSQLNUPS-UHFFFAOYSA-N 0.000 claims description 4
- YCBKSSAWEUDACY-IAGOWNOFSA-N 11-hydroxy-Delta(9)-tetrahydrocannabinol Chemical compound C1=C(CO)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 YCBKSSAWEUDACY-IAGOWNOFSA-N 0.000 claims description 4
- YOVRGSHRZRJTLZ-HZPDHXFCSA-N 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol Chemical compound C1=C(C(O)=O)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 YOVRGSHRZRJTLZ-HZPDHXFCSA-N 0.000 claims description 4
- 244000215068 Acacia senegal Species 0.000 claims description 4
- UVOLYTDXHDXWJU-UHFFFAOYSA-N Cannabichromene Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-UHFFFAOYSA-N 0.000 claims description 4
- SEEZIOZEUUMJME-VBKFSLOCSA-N Cannabigerolic acid Natural products CCCCCC1=CC(O)=C(C\C=C(\C)CCC=C(C)C)C(O)=C1C(O)=O SEEZIOZEUUMJME-VBKFSLOCSA-N 0.000 claims description 4
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 claims description 4
- ZLHQMHUXJUPEHK-UHFFFAOYSA-N Cannabivarin Natural products CCCc1cc(O)c2c(OC(C)(C)c3ccccc23)c1 ZLHQMHUXJUPEHK-UHFFFAOYSA-N 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 229920000084 Gum arabic Polymers 0.000 claims description 4
- IGHTZQUIFGUJTG-QSMXQIJUSA-N O1C2=CC(CCCCC)=CC(O)=C2[C@H]2C(C)(C)[C@@H]3[C@H]2[C@@]1(C)CC3 Chemical compound O1C2=CC(CCCCC)=CC(O)=C2[C@H]2C(C)(C)[C@@H]3[C@H]2[C@@]1(C)CC3 IGHTZQUIFGUJTG-QSMXQIJUSA-N 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 239000000205 acacia gum Substances 0.000 claims description 4
- 235000010489 acacia gum Nutrition 0.000 claims description 4
- WVOLTBSCXRRQFR-DLBZAZTESA-N cannabidiolic acid Chemical compound OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-DLBZAZTESA-N 0.000 claims description 4
- REOZWEGFPHTFEI-UHFFFAOYSA-N cannabidivarine Natural products OC1=CC(CCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-UHFFFAOYSA-N 0.000 claims description 4
- SEEZIOZEUUMJME-FOWTUZBSSA-N cannabigerolic acid Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1C(O)=O SEEZIOZEUUMJME-FOWTUZBSSA-N 0.000 claims description 4
- SEEZIOZEUUMJME-UHFFFAOYSA-N cannabinerolic acid Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1C(O)=O SEEZIOZEUUMJME-UHFFFAOYSA-N 0.000 claims description 4
- SVTKBAIRFMXQQF-UHFFFAOYSA-N cannabivarin Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCC)C=C3OC(C)(C)C2=C1 SVTKBAIRFMXQQF-UHFFFAOYSA-N 0.000 claims description 4
- 235000014633 carbohydrates Nutrition 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 229920001308 poly(aminoacid) Polymers 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 150000003505 terpenes Chemical class 0.000 claims description 4
- 239000000341 volatile oil Substances 0.000 claims description 4
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 claims description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 3
- TZFPIQSSTVIJTQ-HUUCEWRRSA-N (6ar,10ar)-3-butyl-1-hydroxy-6,6,9-trimethyl-6a,7,8,10a-tetrahydrobenzo[c]chromene-2-carboxylic acid Chemical compound C([C@H]1C(C)(C)O2)CC(C)=C[C@H]1C1=C2C=C(CCCC)C(C(O)=O)=C1O TZFPIQSSTVIJTQ-HUUCEWRRSA-N 0.000 claims description 3
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 3
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
- 229920001412 Chicle Polymers 0.000 claims description 3
- 241000723346 Cinnamomum camphora Species 0.000 claims description 3
- YOVRGSHRZRJTLZ-UHFFFAOYSA-N Delta9-THCA Natural products C1=C(C(O)=O)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 YOVRGSHRZRJTLZ-UHFFFAOYSA-N 0.000 claims description 3
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 claims description 3
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 claims description 3
- 229920002079 Ellagic acid Polymers 0.000 claims description 3
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 3
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 3
- 240000001794 Manilkara zapota Species 0.000 claims description 3
- 235000011339 Manilkara zapota Nutrition 0.000 claims description 3
- 239000004698 Polyethylene Substances 0.000 claims description 3
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 3
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 3
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 3
- 239000002174 Styrene-butadiene Substances 0.000 claims description 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 3
- 239000005844 Thymol Substances 0.000 claims description 3
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 3
- 244000273928 Zingiber officinale Species 0.000 claims description 3
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 3
- 235000013871 bee wax Nutrition 0.000 claims description 3
- 239000012166 beeswax Substances 0.000 claims description 3
- MTAZNLWOLGHBHU-UHFFFAOYSA-N butadiene-styrene rubber Chemical compound C=CC=C.C=CC1=CC=CC=C1 MTAZNLWOLGHBHU-UHFFFAOYSA-N 0.000 claims description 3
- 229960000846 camphor Drugs 0.000 claims description 3
- 229930008380 camphor Natural products 0.000 claims description 3
- 235000017663 capsaicin Nutrition 0.000 claims description 3
- 229960002504 capsaicin Drugs 0.000 claims description 3
- 235000012754 curcumin Nutrition 0.000 claims description 3
- 239000004148 curcumin Substances 0.000 claims description 3
- 229940109262 curcumin Drugs 0.000 claims description 3
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 3
- 229960002852 ellagic acid Drugs 0.000 claims description 3
- 235000004132 ellagic acid Nutrition 0.000 claims description 3
- 235000008397 ginger Nutrition 0.000 claims description 3
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims description 3
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 claims description 3
- 239000008173 hydrogenated soybean oil Substances 0.000 claims description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 3
- 239000004816 latex Substances 0.000 claims description 3
- 229920000126 latex Polymers 0.000 claims description 3
- 239000000787 lecithin Substances 0.000 claims description 3
- 235000010445 lecithin Nutrition 0.000 claims description 3
- 229940067606 lecithin Drugs 0.000 claims description 3
- 229930007744 linalool Natural products 0.000 claims description 3
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 3
- 235000012661 lycopene Nutrition 0.000 claims description 3
- 229960004999 lycopene Drugs 0.000 claims description 3
- 239000001751 lycopene Substances 0.000 claims description 3
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 claims description 3
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 claims description 3
- 239000012188 paraffin wax Substances 0.000 claims description 3
- 239000012169 petroleum derived wax Substances 0.000 claims description 3
- 235000019381 petroleum wax Nutrition 0.000 claims description 3
- 229920000573 polyethylene Polymers 0.000 claims description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 3
- 235000013824 polyphenols Nutrition 0.000 claims description 3
- 235000005875 quercetin Nutrition 0.000 claims description 3
- 229960001285 quercetin Drugs 0.000 claims description 3
- 235000021283 resveratrol Nutrition 0.000 claims description 3
- 229940016667 resveratrol Drugs 0.000 claims description 3
- 229940031439 squalene Drugs 0.000 claims description 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 3
- 239000011115 styrene butadiene Substances 0.000 claims description 3
- 229920003048 styrene butadiene rubber Polymers 0.000 claims description 3
- 229930006978 terpinene Natural products 0.000 claims description 3
- 150000003507 terpinene derivatives Chemical class 0.000 claims description 3
- 229960000790 thymol Drugs 0.000 claims description 3
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 2
- 206010042674 Swelling Diseases 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 230000000241 respiratory effect Effects 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 206010048685 Oral infection Diseases 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 206010057190 Respiratory tract infections Diseases 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 abstract description 3
- 239000012730 sustained-release form Substances 0.000 abstract description 3
- 239000010410 layer Substances 0.000 description 23
- 239000004480 active ingredient Substances 0.000 description 21
- 241001608538 Boswellia Species 0.000 description 11
- 235000018062 Boswellia Nutrition 0.000 description 11
- 239000000654 additive Substances 0.000 description 10
- 239000002105 nanoparticle Substances 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 230000001055 chewing effect Effects 0.000 description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 5
- 229920005601 base polymer Polymers 0.000 description 5
- SSNHGLKFJISNTR-DYSNNVSPSA-N (6ar,10ar)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol;2-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1.C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 SSNHGLKFJISNTR-DYSNNVSPSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 239000002621 endocannabinoid Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000003456 ion exchange resin Substances 0.000 description 4
- 229920003303 ion-exchange polymer Polymers 0.000 description 4
- 210000002200 mouth mucosa Anatomy 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 150000001200 N-acyl ethanolamides Chemical class 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229920001971 elastomer Polymers 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 229920001477 hydrophilic polymer Polymers 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 235000017807 phytochemicals Nutrition 0.000 description 3
- 229930000223 plant secondary metabolite Natural products 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 208000008238 Muscle Spasticity Diseases 0.000 description 2
- 229920002550 PolyAPTAC Polymers 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000000806 elastomer Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- GECBBEABIDMGGL-RTBURBONSA-N nabilone Chemical compound C1C(=O)CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 GECBBEABIDMGGL-RTBURBONSA-N 0.000 description 2
- 229960002967 nabilone Drugs 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 229960002715 nicotine Drugs 0.000 description 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 208000018198 spasticity Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 240000007551 Boswellia serrata Species 0.000 description 1
- 235000012035 Boswellia serrata Nutrition 0.000 description 1
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 description 1
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 1
- WVOLTBSCXRRQFR-SJORKVTESA-N Cannabidiolic acid Natural products OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@@H]1[C@@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-SJORKVTESA-N 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- 241000218236 Cannabis Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000008697 Cannabis sativa Nutrition 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229940127450 Opioid Agonists Drugs 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 229940041750 cesamet Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 150000001887 cortisones Chemical class 0.000 description 1
- 230000002198 cosolvency Effects 0.000 description 1
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 1
- 229930007927 cymene Natural products 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 1
- 229960004993 dimenhydrinate Drugs 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 1
- 235000002780 gingerol Nutrition 0.000 description 1
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000874 microwave-assisted extraction Methods 0.000 description 1
- 231100000017 mucous membrane irritation Toxicity 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 238000003815 supercritical carbon dioxide extraction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A61K9/0058—Chewing gums
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Definitions
- the present invention relates to medicinal chewing gum compositions for the treatment of medical conditions and, in particular, to medicinal chewing gum containing a cannabinoid or a derivative thereof and other synergistic compounds for treatment or management of pain, inflammation, swelling, arthritis (osteoarthritis or rheumatoid arthritis), gout, lupus, anxiety, sleep disorders, premenstrual syndrome, asthma, respiratory and oral0 conditions, including infectious diseases (viral, bacterial, and fungal).
- a cannabinoid or a derivative thereof for treatment or management of pain, inflammation, swelling, arthritis (osteoarthritis or rheumatoid arthritis), gout, lupus, anxiety, sleep disorders, premenstrual syndrome, asthma, respiratory and oral0 conditions, including infectious diseases (viral, bacterial, and fungal).
- Cannabinoids are a heteromorphic group of compounds that modulate the endocannabinoid system with many attractive pharmacological actions. They can be classified into three main groups: a) endogenous or endocannabinoids e.g. arachidonoylethanolamide; b)5 natural or phytocannabinoids, which are the active constituents of Cannabis species (e.g. delta- 9-tetrahydrocannabinol (THC) and cannabidiol (CBD)); c) synthetic (e.g. nabilone) (see Table 1).
- endogenous or endocannabinoids e.g. arachidonoylethanolamide
- b)5 natural or phytocannabinoids which are the active constituents of Cannabis species (e.g. delta- 9-tetrahydrocannabinol (THC) and cannabidiol (CBD)
- c) synthetic e.g. nabilone
- Sativex ® by GW Pharmaceuticals, is a buccal spray of THC and CBD in a 1:1 mixture and has been approved in many countries as an adjunctive treatment of neuropathic pain and spasticity associated with multiple sclerosis in adults.
- CesametTM by Bausch Health Co, is a synthetic cannabinoid for oral administration as an anti emetic through a CB1 receptor mediated interaction.
- cannabinoids phytocannabinoids
- the clinical benefits of smoked herb are short and associated with mucosal damage, serious adverse effects, and exposure to carcinogenic by- products.
- the oromucosal route is not suitable for all drugs due the distinctive characteristics of the oral mucosa, including its small surface area as well as its hydrophilic, hydrophobic and enzymatic barriers (e.g. estrases and peptidases).
- absorption via the oral mucosa is prone to lower bioavailability as well as high intra- and inter subject variability.
- Sativex ® by GW Pharmaceuticals, is a commercially available buccal spray of THC and CBD in anon aqueous 1:1 mixture of ethanol and propylene glycol to enhance solubility and permeation. It has been investigated for the treatment of arthritis (W02005120478A1) and approved in many countries as an adjunctive treatment of neuropathic pain and spasticity associated with multiple sclerosis in adults (W02007052013A1). Although designed for buccal absorption, Sativex ® is reported to have a PK profde much like an oral preparation with a variable BA.
- United States patent number 10,004,684 B2 of GW Pharmaceuticals discloses pharmaceutical formulations for use in the administration of lipophilic medicaments including cannabinoids via mucosal surfaces which, upon hydration, form an emulsion mass capable of adhering to the mucosal surface.
- Specific examples disclose a variety of forms including liquid, spray, disintegrating tablet, solid gel and soft gelatin capsule.
- this formulation allows only a limited degree of control over the particle size of the in-situ formed emulsion.
- this system has intrinsic limitations, including susceptibility to microbial growth due to the use of carbohydrate based viscolising agents (carboxymethylcellulose, pre-gelatinised starch), irritation associated with chronic application, as well as a small surface and localized area for contact.
- carbohydrate based viscolising agents carboxymethylcellulose, pre-gelatinised starch
- irritation associated with chronic application as well as a small surface and localized area for contact.
- Another known delivery system is a self-emulsifying dispersible tablet for oromucosal delivery of water insoluble medications including cannabinoids.
- the granules are obtained in the micron range (5-100 mM), the active ingredients are more prone to degradation during the micro granulation process due to the use of high pressure and temperature.
- Another known delivery system disclosed in WO 2017/202424 A1 of Medcan Pharma A/S, is a granulated powdered composition comprising a complex between a cannabinoid and a basic ion exchange resin. Again, the active ingredients are more susceptible to degradation during the granulation process due to the use of temperature and/or aqueous solution.
- Medicated chewing gum is a modem solid dosage form for oromucosal drug delivery. It is used for the delivery of a number of active pharmaceutical ingredients, for example, nicotine, aspirin, dimenhy drinate, vitamins and antifungals.
- MCG offers several advantages. It is a convenient ready -to-use unit dosage with beher perception by patients. It can be used without water and taken at anytime and anywhere. It is a solid dosage form with beher stability than many other dosage forms.
- the active ingredients can be protected from oxygen, light and water. It provides more control over bioavailability, permitting bypass of fist pass metabolism, high BA, local and systemic effects, and has fewer adverse effects.
- MCG remains a niche dosage form due to limitations, including their complex formulation and production requirements, limited characterization and testing methods, and variable drug release due to differences in chewing pattern and rate.
- a known chewing gum composition disclosed in WO 2009/120080 A1 of Mare DA Holding BV, comprises 0.01 to 15 % by weight a cannabinoid or a derivative thereof. During the preparation of this composition, degradation of THC was observed. Furthermore, the extraction of THC was not very efficient.
- Another known chewing gum composition disclosed in WO 2017/059859 A1 of Medcan Pharma A/S, comprises gum base polymers and one or more cannabinoids as an active pharmaceutical ingredient for pain alleviation.
- Other chewing gum preparations compromising cannabinoids with synergistic ingredients are also known, including, gingerol, ginseng, gabapentin, opioid agonists/antagonists and nicotine.
- a medicinal chewing gum has an inner core containing a first gum base and a first cannabinoid in a lipophilic nanosized form and an outer layer containing a second gum base and a second cannabinoid in a hydrophilic nanosized form, thereby providing quick release of the second cannabinoid in the outer layer and sustained release of the first cannabinoid in the inner layer.
- At least one of the inner core and the outer layer contains a synergistic compound having a synergistic effect with at least one of the first and second cannabinoids in the treatment of a medical condition.
- the first gum base of the inner core is a water-insoluble gum base polymer.
- the gum base polymer comprises polyisobutylene-polyethylene oxide (PIB-PEO) graft copolymers in an amount of 50-70% by weight of the gum base polymers, wherein the PIB- PEO graft copolymers include 2.5 - 40% by weight of PEO polymer.
- PIB-PEO polyisobutylene-polyethylene oxide
- the cannabinoid is covalently attached through a biocompatible and biodegradable chemical bond and spacer to a PIB, PEO, or PIB-PEO graft copolymers.
- the PIB is crosslinked with another hydrophilic polymer.
- the PIB may be crosslinked with polyethylene oxide, polyvinyl alcohol, polylysine or other polyaminoacids, hyaluronic acid, or chitosan.
- the outer layer contains the cannabinoid in a nanosized water-soluble form.
- the nanosized water-soluble form may include conjugates or complexes of the cannabinoid.
- the synergistic compound is a gum resin extract from Boswellia sp.
- the present invention may improve the PK and PD profile of cannabinoids, including achieving efficient release and better absorption. This may be attributed to the swelling and solubilization effects imparted by the PEO residues of the PIB-PEO gum base.
- the nanosized form of the cannabinoids increases solubility, stability and surface area of contact available for absorption, while improving their taste.
- the use of the natural gum resins from Boswellia sp. may have synergistic effects in treating medical conditions, such as pain and inflammation, and may further increase the swelling capacity of the gum and hence the bioavailability.
- Figure 1 is a cross-sectional view of a medicinal chewing gum, according to the present invention.
- nano-sized in the present disclosure refers to nanoparticles, micelles, or liposomes with an average size between 20 nm and 200 nm.
- the nanosized forms may be hydrophilic, lipophilic, or amphiphilic based on their composition and preparation.
- cannabinoid in the present disclosure refers to any of the group of chemical compounds that directly or indirectly act on the cannabinoid receptors of cells in a patient. They include numerous phytocannabinoids, such as those found in Cannabis sativa and other plants, and synthetic cannabinoids or endocannabinoids.
- Examples include, but are not limited to: delta-9-tetrahydrocannabinol (THC), delta-8-tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), cannabinolic acid (CBNA), cannabigerol (CBG), cannabigerol (CBG), cannabigerovarin (CBGV), cannabichromene (CBC), cannabicyclol (CBL), canabivarol (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerol monoethyl ether (CBGM), cannabigerolic acid monoethyl ether (CBGAM) cannabidiolic acid (CBD A), cannabigerovarinic (CBGV A), cannabichromenic acid (CBCA), cannabichromenic acid (
- water-soluble cannabinoids in the present disclosure refers to cannabinoid compounds that have been formulated, derivatized, or chemically synthesized in a water-soluble form including sulfate and hemi succinate esters of cannabinoids, or mixtures or combinations thereof.
- extract in the present disclosure refers to compounds from plants that have been extracted and concentrated using one of the many known extraction methods, including solid-phase extraction (SPE), liquid-liquid extraction, ultrasonic and microwave-assisted extraction, heat and mechanochemical-assisted extraction, supercritical carbon dioxide extraction, and hydrocarbon and non-hydrocarbon solvent extracts.
- SPE solid-phase extraction
- patient in the present disclosure refers to human patients but is not limited to humans and may include other species.
- the medicinal chewing gum provides an oromucosal delivery system for cannabinoids and synergistic compounds for the treatment of medical conditions, such as inflammation and pain, with an improved pharmacokinetic/pharmacodynamic profile, compared to some other forms of oral delivery of cannabinoids.
- the medicinal chewing gum provides both short-term quick release of cannabinoids and long-term sustained release of cannabinoids. This is useful in the treatment of medical conditions, such as inflammation and pain, to quickly alleviate symptoms and provide long-lasting relief to the patient.
- the medicinal chewing gum contains active ingredients, synergistic ingredients, a gum base, and additives and fillers, and has an inner core 1 and an outer layer 2, as shown in Figure 1.
- the active ingredients are one or more cannabinoid compounds, which may include: delta-9-tetrahydrocannabinol (THC), delta-8-tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), cannabinolic acid (CBNA), cannabigerol (CBG), cannabigerol (CBG), cannabigerovarin (CBGV), cannabichromene (CBC), cannabicyclol (CBL), canabivarol (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerol monoethyl ether (CBGM), cannabigerolic acid mono
- the active ingredients contained in the medicinal chewing gum are in a nanosized form, having a size of range between 20 nm and 200 nm. Preferably, in the range of 40-100 nm.
- the synergistic ingredients are one or more phytochemicals effective in the treatment of inflammation or pain, which may include active isolates, extracts, or a gum base of: Boswellia sp.. including Boswellia carterii and Boswellia serrata ginger; capsaicin; camphor; polyphenols, including quercetin, ellagic acid, curcumin, and resveratrol; phytosterols; carbohydrates, including mannose-6-phosphate; essential oils, including thymol, and carvacrol; terpenoids, including squalene, lycopene, />cymene. linalool, and carvacrol.
- the phytochemical is a gum base of Boswellia sp., which has a dual purpose as both the gum base of the medicinal chewing gum and as a synergistic ingredient.
- synergistic ingredients are used in the form of a gum base, they may be provided as both the synergistic ingredients and the gum base of the medicinal chewing gum. Alternatively, one or more synergistic ingredients in the form of a gum base may be combined with another gum base in the medicinal chewing gum.
- the gum base is a masticatory natural or synthetic gum base, which may include any of the synergistic ingredients described herein in the form of a gum base, and consist primarily of elastomers, resins, waxes, fats, and emulsifiers.
- Examples include, Gum Arabic, chicle and terpinene resins, beeswax, latex, paraffin, petroleum wax, hydrogenated soybean oil, glycerol monostearate, lecithin, polyethylene, polyvinyl alcohol, styrene-butadiene, polyisobutylene, or a polyisobutylene-polyethylene oxide (PIB-PEO) graft copolymer.
- the gum base could be hydrophilic, lipophilic, or amphiphilic.
- the gum base is amphiphilic in nature and compromises a 1:1, 1:2 or 1:3 mixture of PIB-PEO and Boswellia resins.
- the PIB-PEO to Boswellia resin ratio is 1:1.
- the PEO content of PIB-PEO could vary between 2.5%, 5%, 10%, 20%, 30%, and 40% (%wt).
- the PEO content of the PIB-PEO is 20-40 %wt.
- the PIB gum base may be crosslinked or non-crosslinked. Preferably, it is crosslinked with hydrophilic polymers, such as polyethylene oxide, hyaluronic acid (HA), chitosan, or polyaminoacids.
- hydrophilic polymers such as polyethylene oxide, hyaluronic acid (HA), chitosan, or polyaminoacids.
- HA hyaluronic acid
- chitosan chitosan
- polyaminoacids polyaminoacids.
- the resulting crosslinked PIB gum base and hydrophilic polymers may provide improved biocompatibility, elasticity, and swelling capacity.
- the PIB gum base may be crosslinked with HA, according to the formula below:
- the cannabinoids are physically entrapped within the gum base and are released as the gum is chewed by a patient.
- the cannabinoids may be covalently attached to the polymer backbone of the gum base.
- the gum base contains a mixture of physically entrapped cannabinoids, for relatively faster release and immediate effect, as well as covalently attached cannabinoids, for relatively slower release and sustained effect.
- the cannabinoids may be covalently attached to a PIB gum base or a PIB-PEO gum base, according to the following formula:
- the cannabinoids may be covalently attached to the hydrophilic component of the gum base to increase the release of the cannabinoids during chewing of the gum by the patient.
- the cannabinoids are covalently attached to the PEO component of a PIB-PEO gum base, before grafting the PEO to the PIB, which may also increase the loading of the cannabinoids on the gum base.
- a number of non-masticatory additives and/or fdlers are generally used in chewing gums, whether medicinal or otherwise, in order to provide a desired function and other characteristics of the chewing gum including texture regulating agents, fdlers, and softeners, as well as stabilizing, flavouring, and sweetening agents.
- One or more additives or fdlers are contained in the medicinal chewing gum to provide a desired set of characteristics to the chewing gum, which may include: waxes, sweeteners, flavours, colours, emulsifiers, antioxidants, stabilizers, buffers, enhancers, elastomers, plasticizers, water retention agents, thickening agents, ion exchange resins, or other suitable chewing gum additives and fdlers.
- the ion exchange resins could be strongly or weekly basic.
- the ion exchange resin is strongly basic, for example, poly (acrylamido-N-propyltrimethylammonium chloride) (polyAPTAC).
- the medicinal chewing gum has an inner core 1 and an outer layer 2.
- Each of the inner core 1 and the outer layer 2 contains the active ingredients, a gum base, and additives and fdlers. At least one of the inner core 1 and outer layer 2 contains a synergistic ingredient, preferably both.
- the outer layer 2 differs from the inner core 1 at least in respect of the form in which the active ingredients are provided in each of the respective layers.
- the inner core 1 and outer layer 2 may also contain different or additional synergistic ingredients, gum bases, or additives and fdlers.
- the active ingredients contained in the outer layer 2 are in the form of a hydrophilic or water-soluble preparation, while the active ingredients in the inner core 1 are in the form of a lipophilic preparation.
- the outer layer 2 contains hydrophilic or water- soluble nanoparticles of one or more cannabinoids and the inner core 1 contains lipophilic nanoparticles one or more cannabinoids.
- Nano sized cannabinoids may impart desirable properties including increased solubility, stability, surface area, and absorption.
- the synergistic ingredients may also be contained in the medicinal chewing gum in one or more nanosized forms. Where the synergistic ingredients are in the form of active isolates or extracts, they are combined with the active ingredients and nanoparticles are prepared with the combined ingredients. Preferably, the combined ingredients are used to prepare hydrophilic nanoparticles that are contained in the outer layer 2 and the combination is also used to prepare lipophilic nanoparticles that are contained in the inner core 1.
- the nanosized form could be lipid or solid nanoparticles as well as chelated or encapsulated systems.
- lipid or solid nanoparticles have a size of between 20 nm and 200 nm. Preferably, in the range of 40-100 nm.
- the hydrophilic active ingredients and/or synergistic ingredients in the outer layer 2 provide quick release of the active ingredients and/or synergistic ingredients as the patient initially begins chewing the medicinal chewing gum. This releases a portion of the active ingredients and/or synergistic ingredients substantially immediately to provide rapid onset of the relief of the patient’s symptoms. Preferably, 50 % of the active ingredients and/or synergistic ingredients in the outer layer 2 are released within 5 min of the patient beginning to chew the medicinal chewing gum.
- the lipophilic active ingredients and/or synergistic ingredients in the inner core 1 provide controlled release of the active ingredients and/or synergistic ingredients as the patient continues chewing the medicinal chewing gum. This releases some or all the remaining active ingredients and/or synergistic ingredients over a prolonged period to provide long-lasting relief of the patient’s symptoms. Preferably, 50% of the active ingredients and/or synergistic ingredients in the inner core 1 are released within 15-30 minutes of the patient chewing the medicinal chewing gum.
- the additives and fdlers contained in the inner core 1 may be the same or different from those contained in the outer layer 2, depending on the desired characteristics of each layer.
- the relative proportion of the additives and fdlers may also be the same or different between the inner core 1 and outer layer 2.
- 50-80% of sweeteners and flavouring agents are contained in the outer layer 2 in order to mask the taste and odor of the active ingredients.
- the natural gum base from Boswellia may increase the bioavailability of Cannabinoids because of the expected higher swelling capacity of the medicinal chewing gum.
- the gum base of a medicinal chewing gum may be amphiphilic in nature and may compromise a 1 : 1 , 1:2 or 1:3 mixture of PIB-PEO and Boswellia resins.
- the PIB-PEO to Boswellia resin ratio is 1:1.
- a medicinal chewing gum may be produced by known methods in the literature including a fusion method, cooling/grinding technology, and a direct compression approach. Preferably, the following steps are followed: 1. The gum base is softened or melted (at between 50 - 70 °C) and placed in a mixer.
- Powdered ingredients and additives are then added and mixed.
- phase A The mixture is then cooled, rolled onto plates, and scored into strips to produce the lipophilic inner core (phase A). 4. Gum Arabic is dissolved in water and the water-soluble ingredients and additives, including sweeteners and flavouring agents, are then added and mixed to produce the hydrophilic outer layer (phase B).
- the gum base comprises PIB and Boswellia extract in the %wt ratio of 100:0, 90:10, 80:20, 50:50, 20:80, or 0:100.
- the gum base comprises PIB-PEO and Boswellia extract in the %wt ratio of 100:0, 90:10, 80:20, 50:50, or 20:80.
- the gum base comprises PIB-CBD and Boswellia extract in the %wt ratio of 100:0, 90:10, 80:20, 50:50, or 20:80.
- the gum base comprises PIB-PEO-CBD and Boswellia extract in the %wt ratio of 100:0, 90:10, 80:20, 50:50, or 20:80.
- the gum base comprises PIB-HA and Boswellia extract in the %wt ratio of 100:0, 90:10, 80:20, 50:50, or 20:80.
- An exemplary gum base comprising PIB-CBD or PIB-PEO-CBD may be prepared, according to the formula below, as follows: [0049] Add PIB anhydride (0.2 mmol of anhydride, 1.0 equiv.) to a solution of PEO or CBD, or both (0.4-1 mmol, 2-5 equiv.), and DMAP (0.6 mmol, 3 equiv.) in toluene (5-20.0 mL). Complete the reaction at room temperature for 1-3 days, then wash with HC1 (1 M, 5 mL), water, and brine. Separate the organic layer and dry over anhydrous MgS04, concentrate, and then precipitate in acetone (acetone:toluene 3:1). Wash the resulting rubber with three 5 mL portions of acetone, and then dry in vacuo.
- An exemplary gum base comprising PIB-HA may be prepared as follows. Add a solution of PIB anhydride (1.0 equiv.) in chloroform to a solution of HA (1 equiv.) and dimethoxy PEO (2K, 1 equiv.) in water. Sonicate the mixture using an ultrasonic probe to give a homogenous solution. Evaporate the solvents under vacuum to provide the final crosslinked PIB- HA gum base.
- the medicinal chewing gum has the following composition.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Nanotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Physiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
A medicinal chewing gum has an inner core containing a first gum base and a first cannabinoid in a lipophilic nanosized form and an outer layer containing a second gum base and a second cannabinoid in a hydrophilic nanosized form, thereby providing quick release of the second cannabinoid in the outer layer and sustained release of the first cannabinoid in the inner layer. At least one of the inner core and the outer layer contains a synergistic compound having a synergistic effect with at least one of the first and second cannabinoids in the treatment of a medical condition.
Description
CHEWING GUM CONTAINING CANNABINOIDS AND SYNERGISTIC MEDICINAL COMPOUNDS
Field of the Invention
5 [0001] The present invention relates to medicinal chewing gum compositions for the treatment of medical conditions and, in particular, to medicinal chewing gum containing a cannabinoid or a derivative thereof and other synergistic compounds for treatment or management of pain, inflammation, swelling, arthritis (osteoarthritis or rheumatoid arthritis), gout, lupus, anxiety, sleep disorders, premenstrual syndrome, asthma, respiratory and oral0 conditions, including infectious diseases (viral, bacterial, and fungal).
Background
[0002] Cannabinoids are a heteromorphic group of compounds that modulate the endocannabinoid system with many attractive pharmacological actions. They can be classified into three main groups: a) endogenous or endocannabinoids e.g. arachidonoylethanolamide; b)5 natural or phytocannabinoids, which are the active constituents of Cannabis species (e.g. delta- 9-tetrahydrocannabinol (THC) and cannabidiol (CBD)); c) synthetic (e.g. nabilone) (see Table 1).
Table 1: Representative examples of cannabinoids
[0003] The clinical utility of cannabinoids is well documented in many conditions, including chronic pain, inflammation, neurodegenerative disorders, epilepsy, addiction, insomnia, multiple sclerosis, cancer, obesity, and anorexia. Sativex®, by GW Pharmaceuticals, is a buccal spray of THC and CBD in a 1:1 mixture and has been approved in many countries as an adjunctive treatment of neuropathic pain and spasticity associated with multiple sclerosis in adults. Cesamet™ (nabilone), by Bausch Health Co, is a synthetic cannabinoid for oral administration as an anti emetic through a CB1 receptor mediated interaction.
[0004] Despite their clinical potential, natural cannabinoids (phytocannabinoids) are highly lipophilic (log P 6-7), sparingly soluble in water (solubility = 2-10 pg/mL at 23°C), chemically unstable (particularly in solution via light, temperature, and auto-oxidation), and gummy in nature with erratic absorption, a delayed onset, extensive first-pass metabolism, and low systemic bioavailability after oral administration. Moreover, the clinical benefits of smoked herb are short and associated with mucosal damage, serious adverse effects, and exposure to carcinogenic by- products.
[0005] A variety of formulations and administration methods have been developed in an attempt to overcome some of the limitations of ingested and smoked cannabinoids. Formulation strategies to increase solubility and stability of cannabinoids including derivatization, cosolvency, complexation, as well as surfactant and carrier-assisted methods. [0006] When compared to other routes, drug delivery via the oral mucosa offers many advantages including bypassing first-pass metabolism, avoidance of GIT elimination and gastric
acidity, fast onset of certain drugs due to rich blood supply, possibility of systemic and local delivery, convenience, and patient comfort/compliance. Furthermore, the oral mucosa is robust and tolerant to potential allergens. However, the oromucosal route is not suitable for all drugs due the distinctive characteristics of the oral mucosa, including its small surface area as well as its hydrophilic, hydrophobic and enzymatic barriers (e.g. estrases and peptidases). In addition, absorption via the oral mucosa is prone to lower bioavailability as well as high intra- and inter subject variability.
[0007] Sativex®, by GW Pharmaceuticals, is a commercially available buccal spray of THC and CBD in anon aqueous 1:1 mixture of ethanol and propylene glycol to enhance solubility and permeation. It has been investigated for the treatment of arthritis (W02005120478A1) and approved in many countries as an adjunctive treatment of neuropathic pain and spasticity associated with multiple sclerosis in adults (W02007052013A1). Although designed for buccal absorption, Sativex® is reported to have a PK profde much like an oral preparation with a variable BA. This may be attributed to the dilution effect of the saliva and the reflex swallowing experienced by patients secondary to the non aqueous nature of the delivery system and the associated bad taste, mucosal irritation and hot stinging sensation (~ 25% of patients). Furthermore, Sativex® is inherently prone to chemical instability and degradation because it is in solution form.
[0008] United States patent number 10,004,684 B2 of GW Pharmaceuticals, discloses pharmaceutical formulations for use in the administration of lipophilic medicaments including cannabinoids via mucosal surfaces which, upon hydration, form an emulsion mass capable of adhering to the mucosal surface. Specific examples disclose a variety of forms including liquid, spray, disintegrating tablet, solid gel and soft gelatin capsule. However, this formulation allows only a limited degree of control over the particle size of the in-situ formed emulsion. Moreover, this system has intrinsic limitations, including susceptibility to microbial growth due to the use
of carbohydrate based viscolising agents (carboxymethylcellulose, pre-gelatinised starch), irritation associated with chronic application, as well as a small surface and localized area for contact.
[0009] Another known delivery system, disclosed in WO 2008/033024 A2 of Echo pharmaceuticals B.V., is a self-emulsifying dispersible tablet for oromucosal delivery of water insoluble medications including cannabinoids. Although, the granules are obtained in the micron range (5-100 mM), the active ingredients are more prone to degradation during the micro granulation process due to the use of high pressure and temperature.
[0010] Another known delivery system, disclosed in WO 2017/202424 A1 of Medcan Pharma A/S, is a granulated powdered composition comprising a complex between a cannabinoid and a basic ion exchange resin. Again, the active ingredients are more susceptible to degradation during the granulation process due to the use of temperature and/or aqueous solution.
[0011] Medicated chewing gum (MCG) is a modem solid dosage form for oromucosal drug delivery. It is used for the delivery of a number of active pharmaceutical ingredients, for example, nicotine, aspirin, dimenhy drinate, vitamins and antifungals. When compared to other oromucosal dosage forms (solutions, chewing tablets, adhesive forms, lozenges), MCG offers several advantages. It is a convenient ready -to-use unit dosage with beher perception by patients. It can be used without water and taken at anytime and anywhere. It is a solid dosage form with beher stability than many other dosage forms. The active ingredients can be protected from oxygen, light and water. It provides more control over bioavailability, permitting bypass of fist pass metabolism, high BA, local and systemic effects, and has fewer adverse effects.
[0012] Despite their advantages in oromucosal drug delivery, MCG remains a niche dosage form due to limitations, including their complex formulation and production requirements,
limited characterization and testing methods, and variable drug release due to differences in chewing pattern and rate.
[0013] A known chewing gum composition, disclosed in WO 2009/120080 A1 of Mare DA Holding BV, comprises 0.01 to 15 % by weight a cannabinoid or a derivative thereof. During the preparation of this composition, degradation of THC was observed. Furthermore, the extraction of THC was not very efficient.
[0014] Another known chewing gum composition, disclosed in WO 2017/059859 A1 of Medcan Pharma A/S, comprises gum base polymers and one or more cannabinoids as an active pharmaceutical ingredient for pain alleviation. Other chewing gum preparations compromising cannabinoids with synergistic ingredients are also known, including, gingerol, ginseng, gabapentin, opioid agonists/antagonists and nicotine.
[0015] To minimize the limitations in the prior art, there exists a demand for a new delivery system that improves the pharmacokinetic/pharmacodynamic profile of cannabinoids.
Summary of the Invention [0016] A medicinal chewing gum, according to the present invention, has an inner core containing a first gum base and a first cannabinoid in a lipophilic nanosized form and an outer layer containing a second gum base and a second cannabinoid in a hydrophilic nanosized form, thereby providing quick release of the second cannabinoid in the outer layer and sustained release of the first cannabinoid in the inner layer. At least one of the inner core and the outer layer contains a synergistic compound having a synergistic effect with at least one of the first and second cannabinoids in the treatment of a medical condition.
[0017] In another embodiment, the first gum base of the inner core is a water-insoluble gum base polymer. The gum base polymer comprises polyisobutylene-polyethylene oxide (PIB-PEO)
graft copolymers in an amount of 50-70% by weight of the gum base polymers, wherein the PIB- PEO graft copolymers include 2.5 - 40% by weight of PEO polymer.
[0018] In another embodiment, the cannabinoid is covalently attached through a biocompatible and biodegradable chemical bond and spacer to a PIB, PEO, or PIB-PEO graft copolymers.
[0019] In another embodiment, the PIB is crosslinked with another hydrophilic polymer. For example, the PIB may be crosslinked with polyethylene oxide, polyvinyl alcohol, polylysine or other polyaminoacids, hyaluronic acid, or chitosan.
[0020] In another embodiment, the outer layer contains the cannabinoid in a nanosized water-soluble form. The nanosized water-soluble form may include conjugates or complexes of the cannabinoid.
[0021] In another embodiment, the synergistic compound is a gum resin extract from Boswellia sp.
[0022] When compared to other conventional gum bases, the present invention may improve the PK and PD profile of cannabinoids, including achieving efficient release and better absorption. This may be attributed to the swelling and solubilization effects imparted by the PEO residues of the PIB-PEO gum base. In addition, the nanosized form of the cannabinoids increases solubility, stability and surface area of contact available for absorption, while improving their taste. Furthermore, the use of the natural gum resins from Boswellia sp. may have synergistic effects in treating medical conditions, such as pain and inflammation, and may further increase the swelling capacity of the gum and hence the bioavailability.
Brief Description of the Drawings
[0023] In order that the invention may be more clearly understood, a preferred embodiment thereof will now be described in detail by way of example, with reference to the accompanying drawings, in which: [0024] Figure 1 is a cross-sectional view of a medicinal chewing gum, according to the present invention.
Description of the Invention
[0025] The term “nano-sized” in the present disclosure refers to nanoparticles, micelles, or liposomes with an average size between 20 nm and 200 nm. The nanosized forms may be hydrophilic, lipophilic, or amphiphilic based on their composition and preparation.
[0026] The term “cannabinoid” in the present disclosure refers to any of the group of chemical compounds that directly or indirectly act on the cannabinoid receptors of cells in a patient. They include numerous phytocannabinoids, such as those found in Cannabis sativa and other plants, and synthetic cannabinoids or endocannabinoids. Examples include, but are not limited to: delta-9-tetrahydrocannabinol (THC), delta-8-tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), cannabinolic acid (CBNA), cannabigerol (CBG), cannabigerol (CBG), cannabigerovarin (CBGV), cannabichromene (CBC), cannabicyclol (CBL), canabivarol (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerol monoethyl ether (CBGM), cannabigerolic acid monoethyl ether (CBGAM) cannabidiolic acid (CBD A), cannabigerovarinic (CBGV A), cannabichromenic acid (CBCA), cannabichromenic acid (CBCA), cannabidiol monomethyl ether (CBDM), cannabidiol-C4 (CBD-C4), cannabidivarinic (CBDV A), cannabidiorcol (CBD-C1), delta-9-tetrahydrocannabinolic acid A (THCA-A), delta-9-tetrahydrocannabinolic acid B (THCA-B), delta-9-tetrahydrocannabinolic acid-C4 (THCA-C4), delta-8-tetrahydrocannabinolic acid (delta-8-THCA), delta-8-tetrahydrocannabinol (delta-8-THC), delta-9-
tetrahydrocannabinol-C4 (THC-C4), delta-9-tetrahydrocannabiorcolic acid (THCA-C1), delta- 9-tetrahydrocannabiorcol-Cl (THC-C1), tetrahydrocannabivarinic acid (THCVA), cannabicycobc acid (CBLA), cannbicyclol (CBL), cannabicyclovarin (CBLV), cannabielsoic acid A (CBEA-A), cannabielsoic acid B (CBEA-B), cannabielsoin (CBE), cannabivarin, cannabinol-C4 (CBN-C4), cannabinol methylether (CBNM), cannabiorcol (CBN-C1), cannabinol-C2 (CBN-C2), cannabinodiol (CBND), cannabinodivarin (CBVD), cannabitriol (CBT), cannabitriolvarin (CBTV), dehydrocannabifuran (DCBF), cannabifuran, cannabicitran (CBT), cannabiripsol (CBR), ‘ll-hydroxytetrahydrocannabinoE (11-OH-THC), ‘ll-nor-9- carboxy -tetrahydrocannabinol’ (THC-COOH), or their derivatives, synthetic analogues, or salts, or mixtures or combinations thereof.
[0027] The term “water-soluble cannabinoids” in the present disclosure refers to cannabinoid compounds that have been formulated, derivatized, or chemically synthesized in a water-soluble form including sulfate and hemi succinate esters of cannabinoids, or mixtures or combinations thereof. [0028] The term “extract” in the present disclosure refers to compounds from plants that have been extracted and concentrated using one of the many known extraction methods, including solid-phase extraction (SPE), liquid-liquid extraction, ultrasonic and microwave-assisted extraction, heat and mechanochemical-assisted extraction, supercritical carbon dioxide extraction, and hydrocarbon and non-hydrocarbon solvent extracts. [0029] The term “patient” in the present disclosure refers to human patients but is not limited to humans and may include other species.
[0030] The medicinal chewing gum, according to the present invention, provides an oromucosal delivery system for cannabinoids and synergistic compounds for the treatment of medical conditions, such as inflammation and pain, with an improved
pharmacokinetic/pharmacodynamic profile, compared to some other forms of oral delivery of cannabinoids. The medicinal chewing gum provides both short-term quick release of cannabinoids and long-term sustained release of cannabinoids. This is useful in the treatment of medical conditions, such as inflammation and pain, to quickly alleviate symptoms and provide long-lasting relief to the patient.
[0031] The medicinal chewing gum contains active ingredients, synergistic ingredients, a gum base, and additives and fillers, and has an inner core 1 and an outer layer 2, as shown in Figure 1. The active ingredients are one or more cannabinoid compounds, which may include: delta-9-tetrahydrocannabinol (THC), delta-8-tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), cannabinolic acid (CBNA), cannabigerol (CBG), cannabigerol (CBG), cannabigerovarin (CBGV), cannabichromene (CBC), cannabicyclol (CBL), canabivarol (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerol monoethyl ether (CBGM), cannabigerolic acid monoethyl ether (CBGAM) cannabidiolic acid (CBDA), cannabigerovarinic (CBGV A), cannabichromenic acid (CBCA), cannabichromenic acid (CBCA), cannabidiol monomethylether (CBDM), cannabidiol-C4 (CBD- C4), cannabidivarinic (CBDV A), cannabidiorcol (CBD-C1), delta-9-tetrahydrocannabinobc acid A (THCA-A), delta-9-tetrahydrocannabinobc acid B (THCA-B), delta-9-tetrahydrocannabinobc acid-C4 (THCA-C4), delta-8-tetrahydrocannabinobc acid (delta-8-THCA), delta-8- tetrahydrocannabinol (delta-8-THC), delta-9-tetrahydrocannabinol-C4 (THC-C4), delta-9- tetrahydrocannabiorcobc acid (THCA-C1), delta-9-tetrahydrocannabiorcol-Cl (THC-C1), tetrahydrocannabivarinic acid (THCV A), cannabicycobc acid (CBLA), cannbicyclol (CBL), cannabicyclovarin (CBLV), cannabielsoic acid A (CBEA-A), cannabielsoic acid B (CBEA-B), cannabielsoin (CBE), cannabivarin, cannabinol-C4 (CBN-C4), cannabinol methylether (CBNM), cannabiorcol (CBN-C1), cannabinol-C2 (CBN-C2), cannabinodiol (CBND), cannabinodivarin (CBVD), cannabitriol (CBT), cannabitriolvarin (CBTV), dehydrocannabifuran (DCBF),
cannabifuran, cannabicitran (CBT), cannabiripsol (CBR), ‘ll-hydroxytetrahydrocannabinol’ (11-OH-THC), ‘ll-nor-9-carboxy -tetrahydrocannabinol’ (THC-COOH), or their derivatives, synthetic analogues, or salts, or mixtures or combinations thereof. Preferably, the cannabinoid compound is cannabidiol or tetrahydrocannabinol, or both, or their derivatives, synthetic analogues, or salts.
[0032] The active ingredients contained in the medicinal chewing gum are in a nanosized form, having a size of range between 20 nm and 200 nm. Preferably, in the range of 40-100 nm.
[0033] The synergistic ingredients are one or more phytochemicals effective in the treatment of inflammation or pain, which may include active isolates, extracts, or a gum base of: Boswellia sp.. including Boswellia carterii and Boswellia serrata ginger; capsaicin; camphor; polyphenols, including quercetin, ellagic acid, curcumin, and resveratrol; phytosterols; carbohydrates, including mannose-6-phosphate; essential oils, including thymol, and carvacrol; terpenoids, including squalene, lycopene, />cymene. linalool, and carvacrol. Preferably, the phytochemical is a gum base of Boswellia sp., which has a dual purpose as both the gum base of the medicinal chewing gum and as a synergistic ingredient.
[0034] Where the synergistic ingredients are used in the form of a gum base, they may be provided as both the synergistic ingredients and the gum base of the medicinal chewing gum. Alternatively, one or more synergistic ingredients in the form of a gum base may be combined with another gum base in the medicinal chewing gum. [0035] The gum base is a masticatory natural or synthetic gum base, which may include any of the synergistic ingredients described herein in the form of a gum base, and consist primarily of elastomers, resins, waxes, fats, and emulsifiers. Examples include, Gum Arabic, chicle and terpinene resins, beeswax, latex, paraffin, petroleum wax, hydrogenated soybean oil, glycerol monostearate, lecithin, polyethylene, polyvinyl alcohol, styrene-butadiene, polyisobutylene, or a
polyisobutylene-polyethylene oxide (PIB-PEO) graft copolymer. The gum base could be hydrophilic, lipophilic, or amphiphilic. Preferably, the gum base is amphiphilic in nature and compromises a 1:1, 1:2 or 1:3 mixture of PIB-PEO and Boswellia resins. More preferably, the PIB-PEO to Boswellia resin ratio is 1:1. The PEO content of PIB-PEO could vary between 2.5%, 5%, 10%, 20%, 30%, and 40% (%wt). Preferably the PEO content of the PIB-PEO is 20-40 %wt.
[0036] The PIB gum base may be crosslinked or non-crosslinked. Preferably, it is crosslinked with hydrophilic polymers, such as polyethylene oxide, hyaluronic acid (HA), chitosan, or polyaminoacids. The resulting crosslinked PIB gum base and hydrophilic polymers may provide improved biocompatibility, elasticity, and swelling capacity. In one exemplary embodiment, the PIB gum base may be crosslinked with HA, according to the formula below:
[0037] In some embodiments, the cannabinoids are physically entrapped within the gum base and are released as the gum is chewed by a patient. Alternatively, or additionally, the cannabinoids may be covalently attached to the polymer backbone of the gum base. Preferably, the gum base contains a mixture of physically entrapped cannabinoids, for relatively faster release and immediate effect, as well as covalently attached cannabinoids, for relatively slower release and sustained effect. In one exemplary embodiment, the cannabinoids may be covalently attached to a PIB gum base or a PIB-PEO gum base, according to the following formula:
PIB-CBD PIB-PEO-CBD
[0038] In some embodiments, where the gum base has both lipophilic and hydrophilic components, the cannabinoids may be covalently attached to the hydrophilic component of the gum base to increase the release of the cannabinoids during chewing of the gum by the patient. Preferably, the cannabinoids are covalently attached to the PEO component of a PIB-PEO gum base, before grafting the PEO to the PIB, which may also increase the loading of the cannabinoids on the gum base.
[0039] A number of non-masticatory additives and/or fdlers are generally used in chewing gums, whether medicinal or otherwise, in order to provide a desired function and other characteristics of the chewing gum including texture regulating agents, fdlers, and softeners, as well as stabilizing, flavouring, and sweetening agents. One or more additives or fdlers are contained in the medicinal chewing gum to provide a desired set of characteristics to the chewing gum, which may include: waxes, sweeteners, flavours, colours, emulsifiers, antioxidants, stabilizers, buffers, enhancers, elastomers, plasticizers, water retention agents, thickening agents, ion exchange resins, or other suitable chewing gum additives and fdlers. The ion exchange resins could be strongly or weekly basic. Preferably, the ion exchange resin is strongly basic, for example, poly (acrylamido-N-propyltrimethylammonium chloride) (polyAPTAC).
[0040] The medicinal chewing gum has an inner core 1 and an outer layer 2. Each of the inner core 1 and the outer layer 2 contains the active ingredients, a gum base, and additives and fdlers. At least one of the inner core 1 and outer layer 2 contains a synergistic ingredient, preferably both. The outer layer 2 differs from the inner core 1 at least in respect of the form in which the active ingredients are provided in each of the respective layers. The inner core 1 and outer layer 2 may also contain different or additional synergistic ingredients, gum bases, or additives and fdlers. The active ingredients contained in the outer layer 2 are in the form of a hydrophilic or water-soluble preparation, while the active ingredients in the inner core 1 are in the form of a lipophilic preparation. Preferably, the outer layer 2 contains hydrophilic or water-
soluble nanoparticles of one or more cannabinoids and the inner core 1 contains lipophilic nanoparticles one or more cannabinoids.
[0041] The lipophilic and gummy nature of cannabinoids makes them suitable candidates for advanced nanosized drug delivery methods. Nano sized cannabinoids may impart desirable properties including increased solubility, stability, surface area, and absorption. The synergistic ingredients may also be contained in the medicinal chewing gum in one or more nanosized forms. Where the synergistic ingredients are in the form of active isolates or extracts, they are combined with the active ingredients and nanoparticles are prepared with the combined ingredients. Preferably, the combined ingredients are used to prepare hydrophilic nanoparticles that are contained in the outer layer 2 and the combination is also used to prepare lipophilic nanoparticles that are contained in the inner core 1. The nanosized form could be lipid or solid nanoparticles as well as chelated or encapsulated systems. Preferably, lipid or solid nanoparticles have a size of between 20 nm and 200 nm. Preferably, in the range of 40-100 nm.
[0042] The hydrophilic active ingredients and/or synergistic ingredients in the outer layer 2 provide quick release of the active ingredients and/or synergistic ingredients as the patient initially begins chewing the medicinal chewing gum. This releases a portion of the active ingredients and/or synergistic ingredients substantially immediately to provide rapid onset of the relief of the patient’s symptoms. Preferably, 50 % of the active ingredients and/or synergistic ingredients in the outer layer 2 are released within 5 min of the patient beginning to chew the medicinal chewing gum.
[0043] The lipophilic active ingredients and/or synergistic ingredients in the inner core 1 provide controlled release of the active ingredients and/or synergistic ingredients as the patient continues chewing the medicinal chewing gum. This releases some or all the remaining active ingredients and/or synergistic ingredients over a prolonged period to provide long-lasting relief
of the patient’s symptoms. Preferably, 50% of the active ingredients and/or synergistic ingredients in the inner core 1 are released within 15-30 minutes of the patient chewing the medicinal chewing gum.
[0044] The additives and fdlers contained in the inner core 1 may be the same or different from those contained in the outer layer 2, depending on the desired characteristics of each layer. The relative proportion of the additives and fdlers may also be the same or different between the inner core 1 and outer layer 2. Preferably, 50-80% of sweeteners and flavouring agents are contained in the outer layer 2 in order to mask the taste and odor of the active ingredients.
[0045] Various synergistic effects of phytochemicals are known in the literature. In addition, extracts from Boswellia sp. are known to have an anti-inflammatory effect when administered to a patient on their own and are used as a natural chewing gum in many cultures and as anti inflammatory ingredients in many natural health products. These extracts contain phytosterols with corticosteroid-like activity, however without adverse effects commonly seen with cortisones. They may further increase the swelling capacity of the gum and hence the bioavailability of the active ingredients. Also, they contain terpenoids, essential oils and phytosterols with pain-relief and anti-inflammatory effects. Finally, the natural gum base from Boswellia may increase the bioavailability of Cannabinoids because of the expected higher swelling capacity of the medicinal chewing gum. The gum base of a medicinal chewing gum, according to the present invention, may be amphiphilic in nature and may compromise a 1 : 1 , 1:2 or 1:3 mixture of PIB-PEO and Boswellia resins. Preferably, the PIB-PEO to Boswellia resin ratio is 1:1.
General Methods for Making the Medicinal Chewing Gum
[0046] A medicinal chewing gum, according to the present invention, may be produced by known methods in the literature including a fusion method, cooling/grinding technology, and a direct compression approach. Preferably, the following steps are followed:
1. The gum base is softened or melted (at between 50 - 70 °C) and placed in a mixer.
2. Powdered ingredients and additives are then added and mixed.
3. The mixture is then cooled, rolled onto plates, and scored into strips to produce the lipophilic inner core (phase A). 4. Gum Arabic is dissolved in water and the water-soluble ingredients and additives, including sweeteners and flavouring agents, are then added and mixed to produce the hydrophilic outer layer (phase B).
5. The strips (from phase A) are then coated by the hydrophilic outer layer (from phase B).
6. The medicinal chewing gum is then dried and cut into pieces. Gum Base Examples
[0047] According to one preferred embodiment of the present invention, the gum base comprises PIB and Boswellia extract in the %wt ratio of 100:0, 90:10, 80:20, 50:50, 20:80, or 0:100. In another embodiment, the gum base comprises PIB-PEO and Boswellia extract in the %wt ratio of 100:0, 90:10, 80:20, 50:50, or 20:80. In another embodiment, the gum base comprises PIB-CBD and Boswellia extract in the %wt ratio of 100:0, 90:10, 80:20, 50:50, or 20:80. In another embodiment, the gum base comprises PIB-PEO-CBD and Boswellia extract in the %wt ratio of 100:0, 90:10, 80:20, 50:50, or 20:80. In another embodiment, the gum base comprises PIB-HA and Boswellia extract in the %wt ratio of 100:0, 90:10, 80:20, 50:50, or 20:80.
Gum Base Example 1 [0048] An exemplary gum base comprising PIB-CBD or PIB-PEO-CBD may be prepared, according to the formula below, as follows:
[0049] Add PIB anhydride (0.2 mmol of anhydride, 1.0 equiv.) to a solution of PEO or CBD, or both (0.4-1 mmol, 2-5 equiv.), and DMAP (0.6 mmol, 3 equiv.) in toluene (5-20.0 mL). Complete the reaction at room temperature for 1-3 days, then wash with HC1 (1 M, 5 mL), water, and brine. Separate the organic layer and dry over anhydrous MgS04, concentrate, and then precipitate in acetone (acetone:toluene 3:1). Wash the resulting rubber with three 5 mL portions of acetone, and then dry in vacuo.
Gum Base Example 2
[0050] An exemplary gum base comprising PIB-HA may be prepared as follows. Add a solution of PIB anhydride (1.0 equiv.) in chloroform to a solution of HA (1 equiv.) and dimethoxy PEO (2K, 1 equiv.) in water. Sonicate the mixture using an ultrasonic probe to give a homogenous solution. Evaporate the solvents under vacuum to provide the final crosslinked PIB- HA gum base.
Chewing Gum Example 1
[0051] According to one preferred embodiment of the present invention, the medicinal chewing gum has the following composition.
[0052] The present invention has been described and illustrated with reference to an exemplary embodiment, however, it will be understood by those skilled in the art that various changes may be made and equivalents may be substituted for elements thereof without departing
from the scope of the invention as set out in the following claims. Therefore, it is intended that the invention is not limited to the embodiments disclosed herein.
Claims
1. A medicinal chewing gum, comprising an inner core containing a first gum base and a first cannabinoid in a lipophilic nanosized form and an outer layer containing a second gum base and a second cannabinoid in a hydrophilic nanosized form, wherein at least one of the inner core and the outer layer contains a synergistic compound having a synergistic effect with at least one of the first and second cannabinoids in the treatment of a medical condition.
2. The medicinal chewing gum of claim 1, wherein the first and second cannabinoids are selected from the group consisting of: delta-9-tetrahydrocannabinol (THC), delta-8- tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), cannabinolic acid (CBNA), cannabigerol (CBG), cannabigerol (CBG), cannabigerovarin (CBGV), cannabichromene (CBC), cannabicyclol (CBL), canabivarol (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerol monoethyl ether (CBGM), cannabigerolic acid monoethyl ether (CBGAM) cannabidiolic acid (CBDA), cannabigerovarinic (CBGV A), cannabichromenic acid (CBCA), cannabichromenic acid (CBCA), cannabidiol monomethyl ether (CBDM), cannabidiol-C4 (CBD-C4), cannabidivarinic (CBDV A), cannabidiorcol (CBD-C1), delta-9-tetrahydrocannabinolic acid A (THCA-A), delta-9-tetrahydrocannabinolic acid B (THCA-B), delta-9-tetrahydrocannabinolic acid-C4 (THCA-C4), delta-8-tetrahydrocannabinolic acid (delta-8-THCA), delta-8-tetrahydrocannabinol (delta-8-THC), delta-9- tetrahydrocannabinol-C4 (THC-C4), delta-9-tetrahydrocannabiorcolic acid (THCA-C1), delta- 9-tetrahydrocannabiorcol-Cl (THC-C1), tetrahydrocannabivarinic acid (THCVA), cannabicycolic acid (CBLA), cannbicyclol (CBL), cannabicyclovarin (CBLV), cannabielsoic acid A (CBEA-A), cannabielsoic acid B (CBEA-B), cannabielsoin (CBE), cannabivarin, cannabinol-C4 (CBN-C4), cannabinol methylether (CBNM), cannabiorcol (CBN-C1), cannabinol-C2 (CBN-C2), cannabinodiol (CBND), cannabinodivarin (CBVD), cannabitriol
(CBT), cannabitriolvarin (CBTV), dehydrocannabifuran (DCBF), cannabifuran, cannabicitran (CBT), cannabiripsol (CBR), ‘ll-hydroxytetrahydrocannabinol’ (11-OH-THC), ‘ll-nor-9- carboxy-tetrahydrocannabinor (THC-COOH), and their derivatives, synthetic analogues, and salts, and mixtures and combinations thereof.
3. The medicinal chewing gum of claim 2, wherein the first and second cannabinoids are cannabidiol or a derivative, synthetic analogue, or salt thereof.
4. The medicinal chewing gum of claim 2, wherein the first and second cannabinoids are delta-9-tetrahydrocannabinol or a derivative, synthetic analogue, or salt thereof.
5. The medicinal chewing gum of claim 2, wherein at least one of the first and second gum bases comprises a gum base selected from the group consisting of: polyisobutylene, a polyisobutylene-polyethylene oxide graft copolymer, a polyisobutylene-polyaminoacid graft copolymer, polyisobutylene-hyaluronic acid, polyisobutylene-chitosan, Gum Arabic, chicle and terpinene resins, beeswax, latex, paraffin, petroleum wax, hydrogenated soybean oil, glycerol monostearate, lecithin, polyethylene, polyvinyl alcohol, styrene-butadiene, and a natural gum base of Boswellia sp.
6. The medicinal chewing gum of claim 5, wherein both the first and second gum base comprise a polyisobutylene-polyethylene oxide graft copolymer and a natural gum base of Boswellia sp.
7. The medicinal chewing gum of claim 6, wherein the polyethylene oxide content of the polyisobutylene-poly ethylene oxide graft copolymer is between 2.5 %wt and 40 %wt and the
ratio of the polyisobutylene-polyethylene oxide graft copolymer to the natural gum base of Boswellia sp. is between 1:1 and 1:3.
8. The medicinal chewing gum of claim 7, wherein the polyethylene oxide content of the polyisobutylene-polyethylene oxide graft copolymer is between 20 %wt and 40 %wt and the ratio of the polyisobutylene-polyethylene oxide graft copolymer to the natural gum base of Boswellia sp. is 1:1.
9. The medicinal chewing gum of claim 5, wherein at least one of the first and second gum bases comprises polyisobutylene or a polyisobutylene-poly ethylene oxide graft copolymer and, wherein at least a portion of the first or second cannabinoid is covalently attached to the first or second gum base.
10. The medicinal chewing gum of claim 9, wherein the first gum base comprises a polyisobutylene-poly ethylene oxide graft copolymer and, wherein at least a portion of the first cannabinoid is covalently attached to the polyethylene oxide before grafting the polyethylene oxide to the polyisobutylene of the first gum base.
11. The medicinal chewing gum of claim 2, wherein the synergistic compound is selected from the group consisting of: ginger; capsaicin; camphor; polyphenols, including quercetin, ellagic acid, curcumin, and resveratrol; phytosterols; carbohydrates, including mannose-6- phosphate; essential oils, including thymol, and carvacrol; terpenoids, including squalene, lycopene, p- cymene, linalool, carvacrol, and isolates, extracts, and gum bases of Boswellia sp.
12. The medicinal chewing gum of claim 11 , wherein the synergistic compound is a gum base of Boswellia sp.
13. The medicinal chewing gum of claim 2, wherein the synergistic ingredient is in a nanosized form and, wherein the first or second cannabinoid and the synergistic ingredient are combined prior to preparation of the nanosized form.
14. A method of treating, preventing, or managing a medical condition, comprising: administering to a subject in need thereof a medicinal chewing gum comprising an inner core containing a first gum base and a first cannabinoid in a lipophilic nanosized form and an outer layer containing a second gum base and a second cannabinoid in a hydrophilic nanosized form, wherein at least one of the inner core and the outer layer contains a synergistic compound having a synergistic effect with at least one of the first and second cannabinoids in the treatment of the medical condition; and wherein the medical condition is one or more of pain, inflammation, swelling, osteoarthritis, rheumatoid arthritis, gout, lupus, anxiety, sleep disorders, premenstrual syndrome, asthma, or respiratory or oral infections.
15. The method of claim 14, wherein the first and second cannabinoids are selected from the group consisting of: delta-9-tetrahydrocannabinol (THC), delta-8-tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), cannabinolic acid (CBNA), cannabigerol (CBG), cannabigerol (CBG), cannabigerovarin (CBGV), cannabichromene (CBC), cannabicyclol (CBL), canabivarol (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerol monoethyl ether (CBGM), cannabigerolic acid monoethyl ether (CBGAM) cannabidiolic acid (CBDA), cannabigerovarinic (CBGV A), cannabichromenic acid (CBCA), cannabichromenic acid (CBCA), cannabidiol monomethyl ether
(CBDM), cannabidiol-C4 (CBD-C4), cannabidivarinic (CBDV A), cannabidiorcol (CBD-C1), delta-9-tetrahydrocannabinolic acid A (THCA-A), delta-9-tetrahydrocannabinolic acid B
(THCA-B), delta-9-tetrahydrocannabinolic acid-C4 (THCA-C4), delta-8-tetrahydrocannabinolic acid (delta-8-THCA), delta-8-tetrahydrocannabinol (delta-8-THC), delta-9- tetrahydrocannabinol-C4 (THC-C4), delta-9-tetrahydrocannabiorcolic acid (THCA-C1), delta- 9-tetrahydrocannabiorcol-Cl (THC-C1), tetrahydrocannabivarinic acid (THCVA), cannabicycolic acid (CBLA), cannbicyclol (CBL), cannabicyclovarin (CBLV), cannabielsoic acid A (CBEA-A), cannabielsoic acid B (CBEA-B), cannabielsoin (CBE), cannabivarin, cannabinol-C4 (CBN-C4), cannabinol methylether (CBNM), cannabiorcol (CBN-C1), cannabinol-C2 (CBN-C2), cannabinodiol (CBND), cannabinodivarin (CBVD), cannabitriol (CBT), cannabitriolvarin (CBTV), dehydrocannabifuran (DCBF), cannabifuran, cannabicitran (CBT), cannabiripsol (CBR), ‘ll-hydroxytetrahydrocannabinoE (11-OH-THC), ‘ll-nor-9- carboxy-tetrahydrocannabinoE (THC-COOH), and their derivatives, synthetic analogues, and salts, and mixtures and combinations thereof.
16. The medicinal chewing gum of claim 15, wherein the first and second cannabinoids are cannabidiol or a derivative, synthetic analogue, or salt thereof.
17. The medicinal chewing gum of claim 15, wherein the first and second cannabinoids are delta-9-tetrahydrocannabinol or a derivative, synthetic analogue, or salt thereof.
18. The medicinal chewing gum of claim 15, wherein at least one of the first and second gum bases comprises a gum base selected from the group consisting of: polyisobutylene, a polyisobutylene-polyethylene oxide graft copolymer, a polyisobutylene-polyaminoacid graft copolymer, polyisobutylene-hyaluronic acid, polyisobutylene-chitosan, Gum Arabic, chicle and terpinene resins, beeswax, latex, paraffin, petroleum wax, hydrogenated soybean oil, glycerol monostearate, lecithin, polyethylene, polyvinyl alcohol, styrene-butadiene, and a natural gum base of Boswellia sp.
19. The medicinal chewing gum of claim 18, wherein both the first and second gum base comprise a polyisobutylene-polyethylene oxide graft copolymer and a natural gum base of Boswellia sp.
20. The medicinal chewing gum of claim 19, wherein the polyethylene oxide content of the polyisobutylene-poly ethylene oxide graft copolymer is between 2.5 %wt and 40 %wt and the ratio of the polyisobutylene-polyethylene oxide graft copolymer to the natural gum base of Boswellia sp. is between 1:1 and 1:3.
21. The medicinal chewing gum of claim 20, wherein the polyethylene oxide content of the polyisobutylene-polyethylene oxide graft copolymer is between 20 %wt and 40 %wt and the ratio of the polyisobutylene-polyethylene oxide graft copolymer to the natural gum base of Boswellia sp. is 1:1.
22. The medicinal chewing gum of claim 18, wherein at least one of the first and second gum bases comprises polyisobutylene or a polyisobutylene-polyethylene oxide graft copolymer and, wherein at least a portion of the first or second cannabinoid is covalently attached to the first or second gum base.
23. The medicinal chewing gum of claim 22, wherein the first gum base comprises a polyisobutylene-polyethylene oxide graft copolymer and, wherein at least a portion of the first cannabinoid is covalently attached to the polyethylene oxide before grafting the polyethylene oxide to the polyisobutylene of the first gum base.
24. The medicinal chewing gum of claim 15, wherein the synergistic compound is selected from the group consisting of: ginger; capsaicin; camphor; polyphenols, including quercetin, ellagic acid, curcumin, and resveratrol; phytosterols; carbohydrates, including mannose-e- phosphate; essential oils, including thymol, and carvacrol; terpenoids, including squalene, lycopene, p- cymene, linalool, carvacrol, and isolates, extracts, and gum bases of Boswellia sp.
25. The medicinal chewing gum of claim 24, wherein the synergistic compound is a gum base of Boswellia sp.
26. The medicinal chewing gum of claim 15, wherein the synergistic ingredient is in a nanosized form and, wherein the first or second cannabinoid and the synergistic ingredient are combined prior to preparation of the nanosized form.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20888173.0A EP4058002A4 (en) | 2019-11-12 | 2020-11-12 | Chewing gum containing synergistic medicinal compounds |
US17/776,366 US20230023342A1 (en) | 2019-11-12 | 2020-11-12 | Chewing gum containing synergistic medicinal compounds |
CA3158289A CA3158289A1 (en) | 2019-11-12 | 2020-11-12 | Chewing gum containing synergistic medicinal compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962934061P | 2019-11-12 | 2019-11-12 | |
US62/934,061 | 2019-11-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021092684A1 true WO2021092684A1 (en) | 2021-05-20 |
Family
ID=75911336
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2020/051530 WO2021092684A1 (en) | 2019-11-12 | 2020-11-12 | Chewing gum containing synergistic medicinal compounds |
Country Status (4)
Country | Link |
---|---|
US (1) | US20230023342A1 (en) |
EP (1) | EP4058002A4 (en) |
CA (1) | CA3158289A1 (en) |
WO (1) | WO2021092684A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2022324615A1 (en) | 2021-08-04 | 2024-02-15 | Demeetra Agbio, Inc. | Cannabinoid derivatives and their use |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2377633A (en) * | 2001-05-11 | 2003-01-22 | Gw Pharmaceuticals Ltd | Pharmaceutical compositions comprising the cannabinoids THC and CBD |
WO2008033024A2 (en) * | 2006-09-15 | 2008-03-20 | Echo Pharmaceuticals B.V. | Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances |
WO2019071213A1 (en) * | 2017-10-05 | 2019-04-11 | Receptor Life Sciences, Inc. | Rapid onset and extended action plant-based and synthetic cannabinoid formulations |
WO2020037408A1 (en) * | 2018-08-20 | 2020-02-27 | Hexo Operations Inc. | Cannabis-infused product with controlled cannabinoid profile user experience |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1241949B2 (en) * | 1999-12-30 | 2021-01-06 | Wm. Wrigley Jr. Company | Release of lipophilic active agents from chewing gum |
EP3359142B1 (en) * | 2015-10-07 | 2020-12-09 | NordicCan A/S | Medical chewing gum comprising cannabinoid |
US11529329B2 (en) * | 2016-05-27 | 2022-12-20 | Nordiccan A/S | Powdered composition comprising a complex between a cannabinoid and a basic ion exchange resin |
CN113423279A (en) * | 2019-03-01 | 2021-09-21 | 诺狄更斯公司 | Tabletted cannabinoid chewing gum with layered structure |
-
2020
- 2020-11-12 US US17/776,366 patent/US20230023342A1/en active Pending
- 2020-11-12 EP EP20888173.0A patent/EP4058002A4/en active Pending
- 2020-11-12 WO PCT/CA2020/051530 patent/WO2021092684A1/en unknown
- 2020-11-12 CA CA3158289A patent/CA3158289A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2377633A (en) * | 2001-05-11 | 2003-01-22 | Gw Pharmaceuticals Ltd | Pharmaceutical compositions comprising the cannabinoids THC and CBD |
WO2008033024A2 (en) * | 2006-09-15 | 2008-03-20 | Echo Pharmaceuticals B.V. | Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances |
WO2019071213A1 (en) * | 2017-10-05 | 2019-04-11 | Receptor Life Sciences, Inc. | Rapid onset and extended action plant-based and synthetic cannabinoid formulations |
WO2020037408A1 (en) * | 2018-08-20 | 2020-02-27 | Hexo Operations Inc. | Cannabis-infused product with controlled cannabinoid profile user experience |
Non-Patent Citations (1)
Title |
---|
See also references of EP4058002A4 * |
Also Published As
Publication number | Publication date |
---|---|
US20230023342A1 (en) | 2023-01-26 |
EP4058002A1 (en) | 2022-09-21 |
EP4058002A4 (en) | 2024-01-10 |
CA3158289A1 (en) | 2021-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3046638A1 (en) | Formulations for efficient delivery of cannabinoids | |
EP2063861B1 (en) | Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances | |
CA3106579A1 (en) | Cannabinoid oral dispersible film strip | |
US20160058866A1 (en) | Alternative solutions for the administration of cannabis derived botanical products | |
US8609630B2 (en) | Vitamin B12 compositions | |
CA3040532C (en) | Lozenge for improved delivery of cannabinoids | |
US20200138885A1 (en) | Lipophilic active oral film formulation and method of making the same | |
CA3118594A1 (en) | Lipophilic active oral film formulation and method of making the same | |
CN113710235A (en) | Oral cannabinoid tablets | |
US20230023342A1 (en) | Chewing gum containing synergistic medicinal compounds | |
JP2006316009A (en) | Oral cavity patch and method for producing the same | |
AU2020260255B2 (en) | Cannabinoid lozenge formulation | |
EP3920891B1 (en) | Fast disintegrating cannabinoid tablets | |
WO2021064357A1 (en) | Oral films and a methods for the manufacture and delivery thereof | |
CN113365503A (en) | Cannabinoid chewing gum with high intensity sweetener | |
CA3065042A1 (en) | Fast disintegrating cannabinoid tablets | |
US20240139101A1 (en) | Advanced oral film formulations | |
CN113329743B (en) | Tableted cannabinoid chewing gum with polyvinyl acetate elastomer plasticizer | |
ES2950141T3 (en) | Cannabinoid gum with sugar alcohols | |
WO2012146314A1 (en) | Thin gelatin capsules for rapid drug release in the mouth | |
WO2021195540A1 (en) | Cannabinoid based composition for mitigation of viral effects | |
PL245075B1 (en) | Method of preparing an oral film containing cannabidiol | |
WO2024068991A1 (en) | Soft gummy | |
US20240108663A1 (en) | Soft Gummy | |
Upadhye | Preparation and Characterization of Lyophilized Cyclodextrin Complexes of a Hemisuccinate Ester of Delta-9-Tetrahydrocannabinol for Transmucosal Delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20888173 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3158289 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020888173 Country of ref document: EP Effective date: 20220613 |